宫颈癌患者淋巴结转移分层为大转移、微转移或孤立肿瘤细胞无临床意义:SCCAN项目亚组分析
该研究分析SCCAN数据库中967例宫颈癌患者,评估前哨淋巴结转移大小与无病生存的关系。发现转移灶≥0.4 mm与无病生存显著缩短相关,但传统按大小分层(大转移、微转移、孤立肿瘤细胞)无临床意义。
要点
- 淋巴结转移≥0.4 mm与无病生存显著缩短相关(HR 2.311,P=0.04)。
- 大转移与微转移患者无病生存无显著差异(P=0.484)。
- 孤立肿瘤细胞亚组无病生存与N0无显著差异(P=0.127)。
核心结论
- 宫颈癌患者淋巴结转移灶≥0.4 mm与无病生存显著负相关,未发现转移大小具有优于其余N1患者的预后切点。
- 传统按转移大小分层(大转移、微转移、孤立肿瘤细胞)无临床意义。
研究设计与样本
- 对SCCAN(Surveillance in Cervical CANcer)数据库中967例宫颈癌患者(T1a1L1-T2b)进行亚组分析。
- 患者均接受初次手术治疗,包括前哨淋巴结活检及病理超分期。
- 将前哨淋巴结转移大小视为连续变量,对0.01-1.0 mm的切点值进行多重检验。
- 比较N0与按切点范围定义的N1亚组之间的无病生存。
主要发现
- 172例(18%)患者发现淋巴结转移,其中大转移79例、微转移54例、孤立肿瘤细胞39例。
- 大转移患者无病生存较短(HR 2.20,P=0.003),微转移患者无病生存较短(HR 2.87,P<0.001)。
- 大转移与微转移患者无病生存无显著差异(P=0.484)。
- 孤立肿瘤细胞亚组无病生存与N0无显著差异(P=0.127),与微转移/大转移亚组也无显著差异(P=0.449)。
- 所有转移灶≥0.4 mm的亚组与N0相比无病生存显著缩短(HR 2.311,P=0.04)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 转移灶<0.4 mm的意义因统计效能有限(<80%)无法评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In cervical cancer, presence of lymph-node macrometastases (MAC) is a major prognostic factor and an indication for adjuvant treatment. However, since clinical impact of micrometastases (MIC) and isolated tumor-cells (ITC) remains controversial, we sought to identify a cut-off value for the metastasis size not associated with negative prognosis. METHODS: We analyzed data from 967 cervical cancer patients (T1a1L1-T2b) registered in the SCCAN (Surveillance in Cervical CANcer) database, who underwent primary surgical treatment, including sentinel lymph-node (SLN) biopsy with pathological ultrastaging. The size of SLN metastasis was considered a continuous variable and multiple testing was performed for cut-off values of 0.01-1.0 mm. Disease-free survival (DFS) was compared between N0 and subgroups of N1 patients defined by cut-off ranges. RESULTS: LN metastases were found in 172 (18%) patients, classified as MAC, MIC, and ITC in 79, 54, and 39 patients, respectively. DFS was shorter in patients with MAC (HR 2.20, P = 0.003) and MIC (HR 2.87, P < 0.001), while not differing between MAC/MIC (P = 0.484). DFS in the ITC subgroup was neither different from N0 (P = 0.127) nor from MIC/MAC subgroups (P = 0.449). Cut-off analysis revealed significantly shorter DFS compared to N0 in all subgroups with metastases ≥0.4 mm (HR 2.311, P = 0.04). The significance of metastases <0.4 mm could not be assessed due to limited statistical power (<80%). We did not identify any cut-off for the size of metastasis with significantly better prognosis than the rest of N1 group. CONCLUSIONS: In cervical cancer patients, the presence of LN metastases ≥0.4 mm was associated with a significant negative impact on DFS and no cut-off value for the size of metastasis with better prognosis than N1 was found. Traditional metastasis stratification based on size has no clinical implication.
引用
- Dostálek L, Benešová K, Klát J, et al. Stratification of lymph node metastases as macrometastases, micrometastases, or isolated tumor cells has no clinical implication in patients with cervical cancer: Subgroup analysis of the SCCAN project. Gynecol Oncol. 2022. PMID: 36442426. doi:10.1016/j.ygyno.2022.11.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。